<DOC>
	<DOCNO>NCT01269424</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop divide . O6-benzylguanine may help temozolomide work well make tumor cell sensitive drug . Giving genetically modify peripheral blood stem cell treatment may prevent side effect cause chemotherapy . PURPOSE : This clinical trial study O6-benzylguanine temozolomide combination genetically modify peripheral blood stem cell treat patient newly diagnose glioblastoma multiforme .</brief_summary>
	<brief_title>O6-Benzylguanine Temozolomide With MGMTP140K Genetically Modified Blood Stem Cells Untreated Glioblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate feasibility introduce express P140K MGMT cDNA lentiviral-based provirus autologous hematopoietic stem cell harvest Glioblastoma multiforme ( GBM ) patient . - To assess safety associate infusion autologous hematopoietic stem cell transduce ex vivo lentiviral vector express P140K MGMT patient GBM . Secondary - To determine whether patient receive P140K MGMT-transduced CD34 cell tolerate O6-benzylguanine ( BG ) dose-escalated temozolomide ( TMZ ) without myelosuppression . - To evaluate ability detect P140K-transduced BG TMZ-resistant hematopoietic cell bone marrow peripheral blood patient infuse P140K-transduced CD34 progenitor . - To evaluate feasibility vivo enrichment P140K-expressing hematopoietic cell repeat treatment BG TMZ dose appear therapeutic GBM . - To evaluate efficacy various type chemotherapy without radiotherapy conditioning patient 's bone marrow host transduce autologous hematopoetic stem cell . - To evaluate tumor response , progression-free survival , overall survival . OUTLINE : Patients assign 1 3 treatment cohort . - Cohort 1 ( LV P140K MGMT gene transfer concurrent chemoradiotherapy ) : Patients receive radiotherapy ( 60cGy 30 2cGy daily dos ) TMZ 75mg/m2 /daily 6 week , cell infusion week 7 ( T0 ) follow BG 120 mg/m2 intravenous infusion 1h TMZ 50 mg/m2/day x 5 day , every 28 day ( start T+28 ) 6 cycle . - Cohort 2 ( LV P140K MGMT gene transfer prior concurrent chemoradiotherapy ) : Patients receive BG 120mg/m2 intravenous infusion 1h TMZ 400 mg/m2 one dose give day T-2 T-3 day prior cell infusion , follow within 72-96 hour radiotherapy ( 60cGy 30 2cGy daily dos ) concurrent BG + TMZ 50 mg/m2/day x 5 day , every 28 day , start T+28 total 7 cycle BG + TMZ . - Cohort 3 ( intra-patient dose escalation TMZ patient evidence P140K-marked cell ) : Dose escalation TMZ patient evidence P140K mark cell vivo give describe cohort 1 cohort 2 . After completion radiotherapy , patient receive BG + TMZ 50 mg/m2/day x 5 day . Patients experience grade 3 toxicity increase next TMZ dose level 65 mg/m2/day x 5 . Subsequent dose escalation without grade 3 toxicity 80 mg/m2/day , 100 mg/m2/day , 120mg/m2/day 140 mg/m2/day x 5 . If subsequent cycle grade 3 great hematologic toxicity occur , dose level next cycle reduce one level . Blood sample collect periodically replication-competent lentivirus detection laboratory biomarker study . After completion study therapy , patient follow every 2 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<criteria>Patients histologically confirm , newly diagnose , supratentorial GBM undergone gross total tumor resection near gross total resection ( resection &gt; 90 % enhance tumor demonstrate MRI ) eligible third postoperative week . Patients infratentorial disease , multifocal leptomeningeal disease exclude . In general , patient &gt; 1 cm residual measurable evaluable disease surgical tumor resection . ECOG performance status 02 Karnofsky ≥ 70 . Patients must receive myelosuppressive chemotherapy prior diagnosis GBM . Life expectancy least 12 week . Adequate hematologic ( ANC ≥ 1,000/mm3 , platelet ≥ 100,000/mm3 , Hgb ≥ 9.5 ) , hepatic ( Bilirubin ≤ 2.0 mg/dl , AST ALT less equal 3 time upper limit normal , prothrombin time &lt; 1.2 time normal ) , renal ( Serum creatinine ≤ 2.0 mg/dl Creatinine Clearance ≥ 60mL/min/1.73 m2 subject serum creatinine level institutional normal ) . These test repeat within 2 week treatment BG TMZ , must meet criterion . EKG without evidence acute cardiac disease . Left ventricular ejection fraction ( LVEF ) ≥ 40 Postoperative steroid taper ≤ 24 mg decadron/d Patients childbearing potential must use single barrier contraception Willingness ability provide inform consent . Patient must suture remove prior registration Patient must consider clinically stable . Exclusion criterion : Medical condition associate immunosuppression , active infection medical illness may jeopardize patient safety . HIV seropositivity . This exclusion include two reason . First , evidence decrease marrow reserve HIV+ patient antiviral treatment associate myelosuppression . Thus , drug treatment design myelosuppressive may toxic patient population . Second , extensive laboratory culture bone marrow peripheral blood progenitor cell require . No preclinical sample HIV+ evaluate gene transfer modality propose thus feasibility safety gene transfer selection HIV+ sample yet advocate . Such study plan preclude HIV+ patient later study . Pregnant lactating woman . There data indicate TMZ teratogenic carcinogenic . Thus , use pregnant woman would confer unnecessary risk fetus . Patients symptomatic pulmonary disease severe comorbid condition Patients cardiac insufficiency LVEF &lt; 40 % . History acute coronary event disease arrhythmia within 6 month prior enrollment Prior chemotherapy ( include gliadel wafer ) hematopoietic cell transplantation . Inability undergo repeat MRI evaluation . Prior diagnosis malignant disease within three year period exception surgically cure basal cell carcinoma carcinoma situ cervix Mental incapacity psychiatric illness prevent informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>